This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Drug Enforcement Administration, Department of Justice.
Final order.
This final order establishes the final adjusted 2015 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
This order is effective September 16, 2015.
John R. Scherbenske, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812.
The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the “Controlled Substances Act” and the “Controlled Substances Import and Export Act,” respectively, and are collectively referred to as the “Controlled Substances Act” or the “CSA” for the purposes of this action. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety.
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA. 28 CFR 0.100(b).
The DEA established the initial 2015 aggregate production quotas for controlled substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on September 8, 2014. 79 FR 53216. That notice stated that the DEA could adjust, as needed, the established aggregate production quotas and assessment of annual needs in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. The proposed adjusted 2015 aggregate production quotas for controlled substances in schedules I and II and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on July 8, 2015, 80 FR 39156, in consideration of the outlined criteria. All interested persons were invited to comment on or object to the proposed adjusted 2015 aggregate production quotas and assessment of annual needs on or before August 7, 2015.
Consideration has been given to the criteria outlined in the July 8, 2015, notice of proposed adjusted aggregate production quotas and assessment of annual needs, 80 FR 39156, in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. Five companies submitted timely comments regarding twelve schedule I and II controlled substances. These comments suggested that the proposed adjusted aggregate production quotas for codeine (for sale), fentanyl, gamma hydroxybutric acid, hydrocodone (for sale), methadone, methadone intermediate, methylphenidate, morphine (for conversion), oripavine, oxycodone (for sale), oxymorphone (for conversion), and oxymorphone (for sale) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks. The DEA did not receive any comments related to the proposal not to adjust the 2015 assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine.
In accordance with 21 CFR 1303.13, the DEA has taken into consideration the above comments along with the relevant 2014 year-end inventories, initial 2015 manufacturing and import quotas, 2015 export requirements, actual and projected 2015 sales, research and product development requirements, and the additional quota applications received. Upon consideration of the above, the Administrator determined that the proposed adjusted 2015 aggregate production quotas for dihydroetorphine, ethylmorphine, etorphine HCl, racemethorphan, racemorphan, methylphenidate, and oxycodone (for sale) required additional consideration and hereby further adjusts the proposed 2015 aggregate production quotas for these substances. Regarding codeine (for sale), fentanyl, gamma hydroxybutric acid, hydrocodone (for sale), methadone, methadone intermediate, morphine (for conversion), oripavine, oxymorphone (for conversion), and oxymorphone (for sale) the Administrator hereby determines that the proposed adjusted 2015 aggregate production quotas for these substances as published in the Federal Register on July 8, 2015, 80 FR 39156, are sufficient to meet the current 2015 estimated medical, scientific, research, and industrial needs of the United States and to provide for adequate reserve stock.
As described in the previously published notice establishing the 2015 aggregate production quotas and assessment of annual needs, the DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA included in all schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The final established aggregate production quotas will reflect these included ( printed page 55643) amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event results in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances.
Pursuant to the above, the Administrator hereby finalizes the 2015 aggregate production quotas for the following schedule I and II controlled substances and the 2015 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:
| Basic class | Final adjusted 2015 quotas (g) |
|---|---|
| Schedule I | |
| (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) | 25 |
| [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) | 25 |
| [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) | 15 |
| 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) | 25 |
| 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) | 25 |
| 1-(1-Phenylcyclohexyl)pyrrolidine | 10 |
| 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) | 45 |
| 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) | 45 |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine | 15 |
| 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) | 45 |
| 1-Butyl-3-(1-naphthoyl)indole (JWH-073) | 45 |
| 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) | 45 |
| 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) | 45 |
| 1-Methyl-4-phenyl-4-propionoxypiperidine | 2 |
| 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) | 45 |
| 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) | 45 |
| 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) | 45 |
| 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) | 45 |
| 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) | 45 |
| 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) | 45 |
| 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) | 45 |
| 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) | 30 |
| 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) | 30 |
| 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) | 30 |
| 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) | 30 |
| 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) | 30 |
| 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) | 25 |
| 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) | 30 |
| 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) | 25 |
| 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) | 30 |
| 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) | 15 |
| 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) | 15 |
| 2,5-Dimethoxy-4-ethylamphetamine (DOET) | 25 |
| 2,5-Dimethoxy-4-n-propylthiophenethylamine | 25 |
| 2,5-Dimethoxyamphetamine | 25 |
| 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) | 30 |
| 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) | 30 |
| 3,4,5-Trimethoxyamphetamine | 25 |
| 3,4-Methylenedioxyamphetamine (MDA) | 55 |
| 3,4-Methylenedioxymethamphetamine (MDMA) | 50 |
| 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) | 40 |
| 3,4-Methylenedioxy-N-methylcathinone (methylone) | 50 |
| 3,4-Methylenedioxypyrovalerone (MDPV) | 35 |
| 3-Fluoro-N-methylcathinone (3-FMC) | 25 |
| 3-Methylfentanyl | 2 |
| 3-Methylthiofentanyl | 2 |
| 4-Bromo-2,5-dimethoxyamphetamine (DOB) | 25 |
| 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) | 25 |
| 4-Fluoro-N-methylcathinone (4-FMC) | 25 |
| 4-Methoxyamphetamine | 100 |
| 4-Methyl-2,5-dimethoxyamphetamine (DOM) | 25 |
| 4-Methylaminorex | 25 |
| 4-Methyl-N-ethylcathinone (4-MEC) | 25 |
| 4-Methyl-N-methylcathinone (mephedrone) | 45 |
| 4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) | 25 |
| 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 68 |
| 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) | 53 |
| 5-Methoxy-3,4-methylenedioxyamphetamine | 25 |
| 5-Methoxy-N,N-diisopropyltryptamine | 25 |
| 5-Methoxy-N,N-dimethyltryptamine | 25 |
| Acetyl-alpha-methylfentanyl | 2 |
| ( printed page 55644) | |
| Acetyldihydrocodeine | 2 |
| Acetylmethadol | 2 |
| Allylprodine | 2 |
| Alphacetylmethadol | 2 |
| alpha-Ethyltryptamine | 25 |
| Alphameprodine | 2 |
| Alphamethadol | 2 |
| alpha-Methylfentanyl | 2 |
| alpha-Methylthiofentanyl | 2 |
| alpha-Methyltryptamine (AMT) | 25 |
| alpha-Pyrrolidinobutiophenone (α-PBP) | 25 |
| alpha-Pyrrolidinopentiophenone (α-PVP) | 25 |
| Aminorex | 25 |
| Benzylmorphine | 2 |
| Betacetylmethadol | 2 |
| beta-Hydroxy-3-methylfentanyl | 2 |
| beta-Hydroxyfentanyl | 2 |
| Betameprodine | 2 |
| Betamethadol | 4 |
| Betaprodine | 2 |
| Bufotenine | 3 |
| Cathinone | 70 |
| Codeine methylbromide | 5 |
| Codeine-N-oxide | 305 |
| Desomorphine | 25 |
| Diethyltryptamine | 25 |
| Difenoxin | 11,000 |
| Dihydromorphine | 3,990,000 |
| Dimethyltryptamine | 35 |
| Dipipanone | 5 |
| Fenethylline | 5 |
| gamma-Hydroxybutyric acid | 70,250,000 |
| Heroin | 50 |
| Hydromorphinol | 2 |
| Hydroxypethidine | 2 |
| Ibogaine | 5 |
| Lysergic acid diethylamide (LSD) | 35 |
| Marihuana | 658,000 |
| Mescaline | 25 |
| Methaqualone | 10 |
| Methcathinone | 25 |
| Methyldesorphine | 5 |
| Methyldihydromorphine | 2 |
| Morphine methylbromide | 5 |
| Morphine methylsulfonate | 5 |
| Morphine-N-oxide | 350 |
| N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) | 25 |
| N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) | 25 |
| N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) | 25 |
| N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) | 15 |
| N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) | 15 |
| N,N-Dimethylamphetamine | 25 |
| Naphthylpyrovalerone (naphyrone) | 25 |
| N-Benzylpiperazine | 25 |
| N-Ethyl-1-phenylcyclohexylamine | 5 |
| N-Ethylamphetamine | 24 |
| N-Hydroxy-3,4-methylenedioxyamphetamine | 24 |
| Noracymethadol | 2 |
| Norlevorphanol | 52 |
| Normethadone | 2 |
| Normorphine | 40 |
| Para-fluorofentanyl | 5 |
| Parahexyl | 5 |
| Phenomorphan | 2 |
| Pholcodine | 5 |
| Psilocybin | 30 |
| Psilocyn | 30 |
| Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) | 25 |
| Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) | 25 |
| Tetrahydrocannabinols | 511,250 |
| Thiofentanyl | 2 |
| Tilidine | 25 |
| ( printed page 55645) | |
| Trimeperidine | 2 |
| Schedule II | |
| 1-Phenylcyclohexylamine | 5 |
| 1-Piperidinocyclohexanecarbonitrile | 5 |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) | 2,687,500 |
| Alfentanil | 17,750 |
| Alphaprodine | 3 |
| Amobarbital | 25,125 |
| Amphetamine (for conversion) | 21,875,000 |
| Amphetamine (for sale) | 37,500,000 |
| Carfentanil | 19 |
| Cocaine | 275,000 |
| Codeine (for conversion) | 50,000,000 |
| Codeine (for sale) | 63,900,000 |
| Dextropropoxyphene | 45 |
| Dihydrocodeine | 226,375 |
| Dihydroetorphine | 3 |
| Diphenoxylate (for conversion) | 75,000 |
| Diphenoxylate (for sale) | 1,337,500 |
| Ecgonine | 174,375 |
| Ethylmorphine | 5 |
| Etorphine hydrochloride | 3 |
| Fentanyl | 2,300,000 |
| Glutethimide | 3 |
| Hydrocodone (for conversion) | 137,500 |
| Hydrocodone (for sale) | 99,625,000 |
| Hydromorphone | 7,000,000 |
| Isomethadone | 5 |
| Levo-alphacetylmethadol (LAAM) | 4 |
| Levomethorphan | 30 |
| Levorphanol | 7,125 |
| Lisdexamfetamine | 29,750,000 |
| Meperidine | 6,250,000 |
| Meperidine Intermediate-A | 6 |
| Meperidine Intermediate-B | 32 |
| Meperidine Intermediate-C | 6 |
| Metazocine | 19 |
| Methadone (for sale) | 31,875,000 |
| Methadone Intermediate | 34,375,000 |
| Methamphetamine | 2,061,375 |
| [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] | |
| Methylphenidate | 96,750,000 |
| Morphine (for conversion) | 91,250,000 |
| Morphine (for sale) | 62,500,000 |
| Nabilone | 18,750 |
| Noroxymorphone (for conversion) | 17,500,000 |
| Noroxymorphone (for sale) | 1,475,000 |
| Opium (powder) | 112,500 |
| Opium (tincture) | 687,500 |
| Oripavine | 35,000,000 |
| Oxycodone (for conversion) | 8,350,000 |
| Oxycodone (for sale) | 141,375,000 |
| Oxymorphone (for conversion) | 29,000,000 |
| Oxymorphone (for sale) | 7,750,000 |
| Pentobarbital | 35,000,000 |
| Phenazocine | 6 |
| Phencyclidine | 38 |
| Phenmetrazine | 3 |
| Phenylacetone | 9,375,000 |
| Racemethorphan | 5 |
| Racemorphan | 3 |
| Remifentanil | 4,200 |
| Secobarbital | 215,003 |
| Sufentanil | 6,255 |
| Tapentadol | 12,500,000 |
| Thebaine | 125,000,000 |
| ( printed page 55646) | |
| List I Chemicals | |
| Ephedrine (for conversion) | 1,000,000 |
| Ephedrine (for sale) | 4,000,000 |
| Phenylpropanolamine (for conversion) | 44,800,000 |
| Phenylpropanolamine (for sale) | 8,500,000 |
| Pseudoephedrine (for conversion) | 7,000 |
| Pseudoephedrine (for sale) | 224,500,000 |
Aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.
Dated: September 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-23199 Filed 9-15-15; 8:45 am]
BILLING CODE 4410-09-P